Vitamin K antagonists (VKA) are a group of substances that reduce blood clotting by reducing the action of vitamin K. The term "vitamin K antagonist" is technically a misnomer, as the drugs do not directly antagonize the action of vitamin K in the pharmacological sense, but rather the recycling of vitamin K. Vitamin K antagonists (VKAs) have ...

2020年6月15日 · DOACs are relatively new agents demonstrating superiority or noninferiority to prior standards of care, anticoagulation with vitamin K antagonists (VKA; ie, warfarin), or low‐molecular‐weight heparins (LMWHs), in reducing risk of thromboembolic complications with similar or reduced bleeding risk. 2, 3, 4, 5 Advantages of DOACs compared with ...

This topic review discusses the biology, mechanism of action, and factors that modulate INR control during anticoagulation with a VKA. Separate topics discuss: Warfarin administration – (See "Warfarin and other VKAs: Dosing and adverse effects".) Prevention of bleeding – (See "Risks and prevention of bleeding with oral anticoagulants".)

2024年7月17日 · Recent data indicate that it is safe to use a combination of a VKA and clopidogrel instead of triple antithrombotic therapy (VKA, ASA, and clopidogrel). An increasingly used option is the combination of a direct oral anticoagulant ( DOAC ) with antiplatelet therapy, usually up to 1 year.

In patients beginning vitamin K antago-nist (VKA) therapy, we recommend the initia-tion of oral anticoagulation with doses between 5 mg and 10 mg for the first 1 or 2 days for most individuals, with subsequent dosing based on the international normalized ratio (INR) re-sponse (Grade 1B).

When administered in doses that increase the INR to 2.0–3.0, vitamin K antagonists (VKAs) effectively prevent postoperative VTE in patients in all risk categories. VKAs can be given preoperatively, at the time of surgery, or in the early postoperative period.

VKAs exert their anticoagulant effect by interfering with the cyclic interconversion of vitamin K and its 2,3 epoxide (vitamin K epoxide), modulating the γ-carboxylation of glutamic acid residues...

In patients beginning vitamin K antagonist (VKA) therapy, we recommend the initiation of oral anticoagulation with doses between 5 mg and 10 mg for the first 1 or 2 days for most individuals, with subsequent dosing based on the international normalized ratio (INR) response (Grade 1B).

Patient self-management (PSM) of vitamin K antagonists (VKA) seems a very promising model of care for oral anticoagulation in terms of efficacy and safety. In comparison with other management models of VKA therapy, the number of scientific publications supporting …

It describes the antithrombotic effect of the VKAs, the monitoring of anticoagulation intensity, and the clinical applications of VKA therapy and provides specific management recommendations. Grade 1 recommendations are strong and indicate that the benefits do or do not outweigh the risks, burdens, and costs.